Fatemeh Vahidrodsari Corresponding Author
- Department of Obstetrics and Gynecology, Ghaem Hospital, Mashad University of Medical Sciences, Mashad, Iran
Sedigheh Ayaty
- Department of Obstetrics and Gynecology, Ghaem Hospital, Mashad University of Medical Sciences, Mashad, Iran
Mohammad Taghi Shakeri
- Department of Social Medicine, Biostatics Unit, Faculty of Medicine, Mashad University of Medical Sciences, Mashad, Iran
Sakineh Ghorbani
- Department of Obstetrics and Gynecology, Ghaem Hospital, Mashad University of Medical Sciences, Mashad, Iran

Received: 7/1/2007 Accepted: 7/1/2007 - Publisher : Avicenna Research Institute

Related Articles


Other Format



Introduction: Induced abortion is a medical or surgical termination of pregnancy before the time of fetal viability with maternal or fetal indications. Regarding abundant complications of surgery, anesthesia, need for hospitalization, risk of uterine perforation and other early or late complications, the necessity to terminate pregnancy by medical methods is seriously felt. The aim of this study was to evaluate the efficacy of medical abortion with methotrexate and misoprostol (prosta-glandin E1) at the first trimester of pregnancy. Materials & Methods: This descriptive study was done on 100 women that had been referred at their first trimester of pregnancy to the hospitals of Mashad University of Medical Sciences during 2004 to terminate their pregnancies due to maternal or fetal indications. The data were gathered according to patients' answers to questions and observation of outcomes as the patients went through labor stages. At first, 50mg of methotrexate per unit of body surface area was injected intramuscularly and after 72 hours, the first dose of misoprostol (800µg) was admi-nistered intravaginally. The second dose of misoprostol was repeated 24 hours after the first dose if abortion did not occur. Sonography was performed 7 days after the last dose of misoprostol, to determine the size of probable residue of pregnancy. The gathered data were descriptively analyzed and frequency distributions were assessed by SPSS software. P0.05 was considered significant. Results: Eighty-one women (81%) had successful complete abortions, among whom pregnancy was terminated in 60 cases (74.1%) following the first dose of misoprostol. 40 patients (25.9%) needed a second dose of misoprostol. 21 women had complete abortion, but 19 required curettage. In this study, failure rate was higher in cases with missed abortions (p<0.05 ). duration of uterine content expulsion (p<0.001) were higher in this medically induced abortion. no important side-effects or complications were noted due to methotrexate or misoprostol administration. conclusion: medical abortion in the first trimester of pregnancy with methotrexate and miso-prostol is safe and cost-effective.< pan>

Keywords: Medical abortion, Misoprastol, Methotrexate, First trimester, Pregnancy, Viable fetus, Maternal, Induced abortion, Blighted ovum

To cite this article:


  1. Stubblefield PG. Induced abortion: Indications, coun-seling and services. In: Sciarra JJ. Gynecology & obs-tetrics. Philadelphia: Lippincott Williams & Wilkins. 1993;pp:1050.
  2. Scott JR, Disaia PJ, Hammond CB, Spellacy WN. Danforth’s Obstetries & Gynecology. 9th Edition. Philadelphia, Lippincott Williams & Wilkins. 2003;pp: 561.
  3. Stubblefield PG, Carr-Ellis S, Borgatta L: Methods for inducd abortion. Obstet Gynecol. 2004;104(1):174-85.   [PubMed]
  4. Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S, Atrash HK. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol. 2004;103:729-37.   [PubMed]
  5. Hausknecht RU. Methotrexate and misoprostol to Terminate early pregnancy. N Engl J Med. 1995;31(9): 537-540.   [PubMed]
  6. Lamakov K, Pekhlivanov B, Amaliev I. Medical abor-tion using methotrexate and misoprostol. Efficacy and tolerability Akush Ginekol (Sofiia). 2005;44(3): 16-8.   [PubMed]
  7. Borgatta L, French A, vragovic O, Burnhill MS. Early medical abortion with methotrexate and misoprostol: outcomes and satisfaction among women aged 15-21 years. J Pediatr Adolesc Gynecol. 2001;14 (1):9-16.   [PubMed]
  8. Borgatta L, Burnhill MS, Tyson J, Leonhardt KH, Hausknect RU, Haskell S. Early medical abortion with methotrexate and misoprostol. Obstet Gynecol. 2001; 97(1):11-6.   [PubMed]
  9. Ozeren M, Bileklic, Aydemir V, Bozokaya H, Metho-trexate and misprotol used alone or in combination for early abortion. Contraception. 1999;59(6):389-94.   [PubMed]
  10. Dahiya K, Madan S, Hooda R, Sangwan K , Khosla AH. Evaluation of the efficacy of mifepriston/ miso-prostol and methotrexate for medical abortion. Indian Med Sci. 2005;59(7):301-6.   [PubMed]
  11. Creinin MD, Wiebe E, Gold M. Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol. 1999;12(2):71-7.   [PubMed]
  12. Wiebe ER, Tnouton K. Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. Contraception. 2004;70(6):463-6.   [PubMed]
  13. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103:850.   [PubMed]
  14. Mufftey PE, Stitely ML, Gherman RB. Early intra-uterine pregnancy failure. A randomized trial of medi-cal versus surgical treatment. Am J Obstet Gynecol. 2002;187:321-5.   [PubMed]
  15. Rock JA, Jones HW. Telindes Operative Gynecology. 9th Edition. Lippincott Williams & wilkines. 2003;pp: 496.
  16. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. Williams obstetrics. 22th Edition. New york. MC Graw Hill. 2005;pp:232-47.
  17. Carbonell I, Esteve JL, velazco A, Varela L, Cabezas E, Fernandez C, Sanchaz CJ. Misoprostol 3, 4, or 5 days after methotrexte for early abortion. A randomiz-ed trial. Contraception. 1997;56(3):169-74.   [PubMed]


Home | About Us | Current Issue | Past Issues | Submit a Manuscript | Instructions for Authors | Subscribe | Search | Contact Us

"Journal of Reproduction & Infertility" is owned, published, and managed by Avicenna Research Institute .
Creative Commons License

This work is licensed under a Creative Commons Attribution –NonCommercial 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Journal of Reproductoin and Infertility (JRI) is a member of COMMITTEE ON PUBLICATION ETHICS . Verify here .

©2024 - eISSN : 2251-676X, ISSN : 2228-5482, For any comments and questions please contact us.